Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results of the planned interim analysis (As of 22 Oct 2018; n=293) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 31 Aug 2018 Biomarkers information updated